Urs Wiedemann is a panelist on a workshop entitled “Let’s get personal: Advances in precision medicine are changing the way we identify and treat disease.”
CRA is a silver sponsor for this annual conference.
For more information on this event, click here.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...